Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, announces that Dr Paul Harper is standing down from the role of Non-Executive Chairman and as a Director of the Company with immediate effect. Dr Harper has served the Company since 2004 as Non-Executive Director, and since 2007 as Chairman, and the Board would like to express its thanks for his contribution and long service.
Dr Jim Millen will retain the role of CEO of Physiomics and additionally assume the role of Executive Chairman, but no other board changes will be made immediately. The Company is seeking to appoint at least one independent Non-Executive Director as soon as possible and a further announcement in this regard will be made in due course.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
For more information please visit: